Skip to main content

Advertisement

SpringerLink
Log in

Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Introduction

Fibroblast growth factor-23 plays an important role in regulating systemic phosphate homeostasis, and vitamin D metabolism. However, the effect of Cholecalciferol therapy on FGF23 serum level in patients with vitamin D deficiency has not been studied, yet.

Materials and methods

This is a double-blind, randomized clinical trial on 119 vitamin D deficient patients in 2016. Biochemical variables of treatment and placebo groups were analyzed after 12 weeks of 50,000 IU of Cholecalciferol vs. placebo therapy once a week, by SPSS18.

Results

After Cholecalciferol therapy, delta of serum PTH in treatment group was less than the controls (P < 0.001). However, delta values of serum 25(OH)D3, 1,25(OH)2D3 and FGF23 in vitamin D treated group were more than the placebo-treated ones (P < 0.001, P = 0.002, and P = 0.04, respectively). Moreover, FGF23 serum level in treatment group was associated with serum calcium (P = 0.005, r = −0.256), and serum 1,25(OH)2D3 (P < 0.001, r = 0.529).

Conclusions

We propose that in these patients 1,25(OH)2D3 has a positive association with serum FGF23, and hypostasized that serum calcium might be a down regulator of serum FGF23.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N (2002) Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265–28270

    Article  CAS  PubMed  Google Scholar 

  2. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2004) Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD (2010) Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5(1):110–116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Quarles LD (2012) Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 318(9):1040–1048

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ranch D, Zhang MY, Portale AA, Perwad F (2011) Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res 26(8):1883–1890

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S (2004) Yamashita T.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429–435

    Article  CAS  PubMed  Google Scholar 

  7. Prié D, Friedlander G (2010) Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol 5(9):1717–1722

    Article  PubMed  Google Scholar 

  8. Haussler MR, Whitfield GK, Kaneko I, Forster R, Saini R, Hsieh JC, Haussler CA, Jurutka PW (2012) The role of vitamin D in the FGF23, Klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord 13(1):57–69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67:1120–1125

    Article  CAS  PubMed  Google Scholar 

  10. Hsu HJ, Wu MS (2009) Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 337:116–122

    Article  PubMed  Google Scholar 

  11. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18:2600–2608

    Article  CAS  PubMed  Google Scholar 

  12. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549

    Article  CAS  PubMed  Google Scholar 

  13. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR (2005) Ghishan FK.1alpha, 25-dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289(6):G1036–G1042

    Article  CAS  PubMed  Google Scholar 

  14. Ashouri E, Meimandi EM, Saki F, Dabbaghmanesh MH, Omrani GR, Bakhshayeshkaram M (2015) The impact of LRP5 polymorphism (rs556442) on calcium homeostasis, bone mineral density, and body composition in Iranian children. J Bone Miner Metab 33(6):651–657. doi:10.1007/s00774-014-0624-4

    Article  CAS  PubMed  Google Scholar 

  15. Soliman AT, De Sanctis V, Elalaily R, Bedair S, Kassem I (2014) Vitamin D deficiency in adolescents.Indian. J Endocrinol Metab 18(Suppl 1):S9–S16

    Google Scholar 

  16. Saki F, Dabbaghmanesh MH, Omrani GR, Bakhshayeshkaram M (2015) Vitamin D deficiency and its associated risk factors in children and adolescents in southern Iran. Public Health Nutr 8:1–6

    Google Scholar 

  17. Saki F, Omrani GR, Pouralborz Y, Dabbaghmanesh MH (2017) Vitamin D deficiency and the associated factors in children with type 1 diabetes mellitus in southern Iran. Int J Diabetes Dev Ctries 37(1):78–84

    Article  CAS  Google Scholar 

  18. Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest. 116:2062–2072

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T (2005) Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289(5):F1088–F1095

    Article  CAS  PubMed  Google Scholar 

  20. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349

    Article  CAS  PubMed  Google Scholar 

  21. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M (2005) Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 101:94–99

    Article  Google Scholar 

  22. Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 study team (2014) Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate. Antivir Ther 19(6):613–618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17(5):1305–1315

    Article  CAS  PubMed  Google Scholar 

  24. Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS (2012) Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol 7(4):624–631

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ghazi AA, Hosseinpanah F, Ardakani ME, Ghazi S, Hedayati M, Azizi F (2010) Effects of different doses of oral Cholecalciferol on serum 25(OH)D, PTH, calcium and bone markers during fall and winter in school children. Eur J Clin Nutr 64(12):1415–1422

    Article  CAS  PubMed  Google Scholar 

  26. Hruska KA, Rifas L, Cheng SL, Gupta A, Halstead L, Avioli L (1995) X-linked hypophosphatemic rickets and the murine Hyp homologue. Am J Physiol 268:357–362

    Google Scholar 

  27. Liu S, Quarles LD (2004) FGF23: the counter regulatory phosphaturic hormone for vitamin D-mediated hyperphosphatemia. J Bone Minner Res. 19:251

    Google Scholar 

  28. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto K (2005) Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288(6):E1101–E1109

    Article  CAS  PubMed  Google Scholar 

  29. Clinkenbeard EL, White KE (2016) Systemic control of bone homeostasis by FGF23 signaling. Curr Mol Biol Rep 2(1):62–71

    Article  PubMed  PubMed Central  Google Scholar 

  30. David V, Dai B, Martin A, Huang J, Han X, Quarles LD (2013) Calcium regulates FGF-23 expression in bone. Endocrinology 154(12):4469–4482

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by the Shiraz University of Medical Sciences with the Grant Number: 94-01-49-10264. The authors wish to thank the Research Consultation Center (RCC) at Shiraz University of Medical Sciences for their invaluable assistance in editing this article.

Author information

Authors and Affiliations

  1. Shiraz Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, P.O. Box: 71345-1744, Shiraz, Iran

    T. Kamelian, F. Saki, M. Jeddi, M. H. Dabbaghmanesh & G. H. R. Omrani

Authors
  1. T. Kamelian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Saki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Jeddi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. H. Dabbaghmanesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. H. R. Omrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to F. Saki or G. H. R. Omrani.

Ethics declarations

Conflict of interest

Tectom Kamelian, Gholamhossein Ranjbar Omrani, MarjanJeddi and Forough Saki declare that they have no conflict of interest.

Ethical approval

Shiraz University of Medical Sciences ethic committee approved this study with number 94-01-49-10264.

Informed consent

All the patients signed a written informed consent.

Funding

There is no financial support.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamelian, T., Saki, F., Jeddi, M. et al. Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial. J Endocrinol Invest 41, 299–306 (2018). https://doi.org/10.1007/s40618-017-0739-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-017-0739-2

Keywords

Search

Navigation